Amgen Inc (AMGN)vsCanadian Natural Resources Ltd (CNQ)
AMGN
Amgen Inc
$348.77
-1.24%
HEALTHCARE · Cap: $187.83B
CNQ
Canadian Natural Resources Ltd
$50.09
+2.92%
ENERGY · Cap: $101.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Canadian Natural Resources Ltd generates 5% more annual revenue ($38.76B vs $36.75B). CNQ leads profitability with a 27.9% profit margin vs 21.0%. AMGN appears more attractively valued with a PEG of 2.33. AMGN earns a higher WallStSmart Score of 70/100 (B-).
AMGN
Strong Buy70
out of 100
Grade: B-
CNQ
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.6%
Fair Value
$665.50
Current Price
$348.77
$316.73 discount
Margin of Safety
+76.8%
Fair Value
$175.50
Current Price
$50.09
$125.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Revenue surging 150.0% year-over-year
Earnings expanding 372.3% YoY
Large-cap with strong market position
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
Trading at 21.7x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bull Case : CNQ
The strongest argument for CNQ centers on Revenue Growth, EPS Growth, Market Cap. Profitability is solid with margins at 27.9% and operating margin at 19.6%. Revenue growth of 150.0% demonstrates continued momentum.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book.
Bear Case : CNQ
The primary concerns for CNQ are PEG Ratio.
Key Dynamics to Monitor
AMGN profiles as a mature stock while CNQ is a growth play — different risk/reward profiles.
CNQ carries more volatility with a beta of 1.06 — expect wider price swings.
CNQ is growing revenue faster at 150.0% — sustainability is the question.
CNQ generates stronger free cash flow (2.3B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (70/100 vs 67/100), backed by strong 21.0% margins. CNQ offers better value entry with a 76.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Canadian Natural Resources Ltd
ENERGY · OIL & GAS E&P · USA
Canadian Natural Resources Limited acquires, explores, develops, produces, markets and sells crude oil, natural gas and natural gas liquids (NGL). The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?